Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03163693
Other study ID # 2015-NW-028
Secondary ID
Status Active, not recruiting
Phase N/A
First received May 15, 2017
Last updated May 20, 2017
Start date February 2016
Est. completion date May 2017

Study information

Verified date May 2017
Source General Hospital of Ningxia Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to observe the impact of dexmedetomidine on Cardiac Troponin I and Glycogen Phosphorylase Isoenzyme BB in patients undergoing off-pump coronary artery bypass Grafting.


Description:

Dexmedetomidine is a highly selective α2-adrenoceptor agonist used as a sedative or adjuvant anesthetic drug in clinical settings.From clinical observation, dexmedetomidine has been revealed to reduce the incidence of cardiovascular adverse events in patients with heart diseases during non‑cardiac surgeries.Therefore, the aim of this sudy is to observe the impact of dexmedetomidine on Cardiac Troponin I and Glycogen Phosphorylase Isoenzyme BB in patients during cardiac surgeries.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 40
Est. completion date May 2017
Est. primary completion date May 2017
Accepts healthy volunteers No
Gender All
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria:

- Patients undergoing off - pump coronary artery bypass grafting

- ASA physical status III-IV

- Aged 40-70 years

- NYHA physical status II-III

Exclusion Criteria:

- Bradycardia

- Atrioventricular block

- Echocardiography suggested:LVEF <40%, LVED>65mm

- Allergic to the drugs

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
dexmedetomidine
receive dexmedetomidine 0.5 µg/kg
Other:
normal saline
receive equal volume of normal saline

Locations

Country Name City State
China General Hospital of Ningxia Medical University Yinchuan Ningxia

Sponsors (1)

Lead Sponsor Collaborator
General Hospital of Ningxia Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of cardiac troponin I at preoperative, postoperative,and 24 hours after surgery. Blood samples were sampled at preoperative, postoperative,and 24 hours after surgery for the cTnI,which were analyzed by using enzyme linked immunosorbent assay (ELISA). At preoperative, postoperative,and 24 hours after surgery.
Primary Change of Glycogen Phosphorylase Isoenzyme BB at preoperative, postoperative,and 24 hours after surgery. Blood samples were sampled at preoperative, postoperative,and 24 hours after surgery for the GP-BB,which were analyzed by using enzyme linked immunosorbent assay (ELISA). At preoperative, postoperative,and 24 hours after surgery.
See also
  Status Clinical Trial Phase
Recruiting NCT06399627 - Effect of Non-anemic Iron Deficiency on Outcome Following Off-pump Coronary Revascularization
Completed NCT03889730 - Intraoperative Hypotension and Acute Kidney Injury After Off-pump Coronary Artery Bypass Grafting Surgery
Terminated NCT02046824 - Cell Savers and Blood Quality N/A
Recruiting NCT03629418 - Targeted Blood-pressure Management and Acute Kidney Injury After Coronary Artery Bypass Surgery N/A
Recruiting NCT04267835 - Prospective Cohort Study on Minimal Invasive Coronary Surgery
Not yet recruiting NCT04795193 - Efficacy and Safety of Minimal Invasive Coronary Surgery in Patients With Complex Coronary Artery Lesions N/A